The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)

Filter results
Date Title Content PDF
5/09/2019 Others on business performance and financial information The Company informs about the construction of a second heparin plant in Granada
30/07/2019 Information on P&L ROVI releases the press release related to the first half 2019 financial results
30/07/2019 Information on P&L ROVI releases the first half 2019 results presentation
5/07/2019 R&D: new licenses, patents and registered trademarks ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia.
2/07/2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the second quarter of 2019
26/06/2019 Información sobre dividendos The Company informs about the dividends payment
12/06/2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its General Shareholders Meeting
8/05/2019 Information on P&L ROVI releases the press release related to the first quarter 2019 financial results
8/05/2019 Information on P&L ROVI releases the first quarter 2019 results presentation
8/05/2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its 2019 General Shareholders Meeting

Pages